Effective 19 May 2017, Pavco
will become a member of the company's scientific advisory board where her expertise in the field of oligonucleotides and the development of RNAi therapeutics will continue to support RXi's ongoing research and development initiatives.
Un estudio cualitativo de caso en la planta de Pavco
en Guachene - Cauca.
, Chief Development Officer with RXi, chaired a panel discussion entitled 'Oligonucleotide-based Therapeutics: 20 Years from Concept to Clinical Validation' at the June 2012 Bio International Convention in Boston, Massachusetts.
This is an exciting time for RXi Pharmaceuticals, and for RNAi technology in general," said Pamela Pavco
, Chief Development Officer for the company.
We are pleased with the progress the company is making with RXI-109 and continue to be on track to file an IND in the second half of this year," said Pamela Pavco
Joanne Kamens, Dmitry Samarsky and Pamela Pavco
will be speaking at the IBC TIDES Oligonucleotide and Peptide[R] Technology and Product Development Conference and the IBC Oligonucleotide Therapeutics Discovery Conference co-located in Boston, Massachusetts on April 25 - 28, 2010.
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco
A native of Vermont, Miller gained his electronic know-how while serving in the Air Force, and later worked with Geophysical Engineers, Linear Corporation and Pavco
Electronics before branching out to form AMX.
who co-invented and commercialized STEALTH(TM) RNAi; CFO, Jim Warren, former CFO of Aquila Biopharmaceuticals, Harvard BioScience and ActivBiotics and VP and Corporate Controller at Genzyme; VP of Pharmaceutical Development; Pamela Pavco
brings a demonstrated success in RNA drug development to the RXi team.